LUNG PE Ratio & Valuation, Is LUNG Overvalued

Historical Valuation

Pulmonx Corp (LUNG) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.04 is considered Undervalued compared with the five-year average of -10.03. The fair price of Pulmonx Corp (LUNG) is between 6.58 to 20.98 according to relative valuation method. Compared to the current price of 1.17 USD , Pulmonx Corp By Undervalued By 82.22%.

Relative Value

Fair Zone

6.58-20.98

Current Price：1.17

82.22%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Pulmonx Corp (LUNG) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Pulmonx Corp (LUNG) has a current Price-to-Book (P/B) ratio of 1.58. Compared to its 3-year average P/B ratio of 2.67, the current P/B ratio is approximately -40.73% higher. Relative to its 5-year average P/B ratio of 3.59, the current P/B ratio is about -55.92% higher. Pulmonx Corp (LUNG) has a Forward Free Cash Flow (FCF) yield of approximately -34.33%. Compared to its 3-year average FCF yield of -17.86%, the current FCF yield is approximately 92.28% lower. Relative to its 5-year average FCF yield of -13.20%, the current FCF yield is about 160.10% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LUNG competitors is 23.53, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG.O) exhibits a P/S ratio of 1.04, which is -95.56% above the industry average. Given its robust revenue growth of -4.91%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LUNG increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LUNG in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LUNG currently overvalued or undervalued?

What is Pulmonx Corp (LUNG) fair value?

LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Pulmonx Corp (LUNG) is between 6.58 to 20.98 according to relative valuation method.

How does LUNG's valuation metrics compare to the industry average?

The average P/S ratio for LUNG's competitors is 23.53, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of 1.04, which is -95.56% above the industry average. Given its robust revenue growth of -4.91%, this premium appears unsustainable.

What is the current P/B ratio for Pulmonx Corp (LUNG) as of Mar 30 2026?

As of Mar 30 2026, Pulmonx Corp (LUNG) has a P/B ratio of 1.58. This indicates that the market values LUNG at 1.58 times its book value.

What is the current FCF Yield for Pulmonx Corp (LUNG) as of Mar 30 2026?

As of Mar 30 2026, Pulmonx Corp (LUNG) has a FCF Yield of -34.33%. This means that for every dollar of Pulmonx Corp's market capitalization, the company generates -34.33 cents in free cash flow.

What is the current Forward P/E ratio for Pulmonx Corp (LUNG) as of Mar 30 2026?

As of Mar 30 2026, Pulmonx Corp (LUNG) has a Forward P/E ratio of -1.65. This means the market is willing to pay $-1.65 for every dollar of Pulmonx Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Pulmonx Corp (LUNG) as of Mar 30 2026?

As of Mar 30 2026, Pulmonx Corp (LUNG) has a Forward P/S ratio of 1.04. This means the market is valuing LUNG at $1.04 for every dollar of expected revenue over the next 12 months.

LUNG Valuation